{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of June 2023): No"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2718019"],"location":["United States"],"study_start_month":["8"],"keyword":["Refractory metastatic colorectal cancer","Relapsed metastatic colorectal cancer","Chimeric antigen receptors (CAR)"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"GCC19CART for Patients With Metastatic Colorectal Cancer","description":"Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.","dates":{"creation":"2022-08-15"},"accession":"2718019","cross_references":{"ClinicalTrials___gov":["NCT05319314"]}}